COVID-19 vaccine candidate from China's CNBG promising in human test, says study |
Journal Updates
eMediNexus Coverage from: 
COVID-19 vaccine candidate from China's CNBG promising in human test, says study

0 Read Comments                

One of China’s COVID-19 vaccine candidates has been found to be safe and evoked immune responses in a combined early and mid-stage test in humans, noted researchers.

The potential vaccine, BBIBP-CorV, being developed by the Beijing Institute of Biological Products, a subsidiary of China National Biotec Group (CNBG), has already received approval for an emergency inoculation program in China which targets essential workers and other limited groups of people having a high infection risk. Whether the vaccine can safely protect people from COVID-19 will only become clear after final Phase III trials are complete.

BBIBP-CorV is among at least 10 coronavirus vaccine projects across the world that have entered Phase III trials. It did not lead to any severe side effects.The common mild or moderate adverse reactions included fever and pain at injection sites, reported a paper published in the Lancet… (Reuters, October 16, 2020)

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now